Inactive Instrument
Guided Therapeutics Inc Share Price OTC Bulletin Board
Stocks
US40171F2048
Advanced Medical Equipment & Technology
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 16/06 | Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA | CI |
| 15/05 | Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 2.8Cr 2.44Cr 2.25Cr 2.12Cr 3.96Cr 263.85Cr 3.98Cr 27Cr 10Cr 130.03Cr 11Cr 10Cr 450.68Cr | P/E 2024 |
-3x | P/E 2025 | -12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3.09Cr 2.69Cr 2.48Cr 2.33Cr 4.36Cr 290.95Cr 4.39Cr 30Cr 11Cr 143.39Cr 12Cr 11Cr 496.98Cr | EV / Sales 2024 |
1,649x | EV / Sales 2025 | 64.4x |
| Free-Float |
63.48% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Faupel
CEO | Chief Executive Officer | 70 | 06/03/2023 |
| Chief Tech/Sci/R&D Officer | 70 | 02/12/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Faupel
BRD | Director/Board Member | 70 | 01/12/2016 |
John Imhoff
BRD | Director/Board Member | 76 | 10/04/2006 |
Michael James
CHM | Chairman | 67 | 01/10/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.63% | -2.32% | +18.35% | -13.53% | 17TCr | ||
| +1.14% | -1.48% | -20.16% | +23.51% | 14TCr | ||
| -0.33% | -2.00% | -8.88% | -26.73% | 13TCr | ||
| +0.76% | -3.99% | -55.32% | -16.62% | 6.73TCr | ||
| +0.78% | +1.87% | +18.09% | -4.98% | 5.03TCr | ||
| +0.04% | -0.90% | -25.23% | -34.48% | 4.41TCr | ||
| +2.20% | -1.92% | +9.99% | +4.90% | 3.59TCr | ||
| -0.44% | -1.20% | +4.74% | +32.04% | 3.49TCr | ||
| +0.72% | -4.53% | -14.33% | -21.69% | 2.8TCr | ||
| Average | +0.61% | -2.12% | -8.08% | -6.40% | 7.81TCr | |
| Weighted average by Cap. | +0.58% | -2.00% | -6.62% | -6.41% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 7T 6.1T 5.62T 5.29T 9.89T 7L 9.96T 66.89T 25.98T 3L 26.27T 25.71T 11.27L | 8L 7L 6L 6L 10.84L 7.23Cr 10.92L 73.29L 28.46L 3.56Cr 28.79L 28.17L 12Cr |
| Net income | -24.17L -21.06L -19.41L -18.26L -34.16L -23Cr -34.4L -2.31Cr -89.7L -11Cr -90.72L -88.78L -39Cr | -31.96L -27.85L -25.67L -24.15L -45.17L -30Cr -45.49L -3.05Cr -1.19Cr -15Cr -1.2Cr -1.17Cr -51Cr |
| Net Debt | 17.71L 15.43L 14.22L 13.38L 25.03L 17Cr 25.21L 1.69Cr 65.72L 8.23Cr 66.47L 65.05L 29Cr | 28.76L 25.06L 23.1L 21.73L 40.65L 27Cr 40.93L 2.75Cr 1.07Cr 13Cr 1.08Cr 1.06Cr 46Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















